Crinetics Pharmaceuticals, Inc.
$40.25
▲
1.8%
2026-04-21 06:14:01
www.crinetics.com
NMS: CRNX
Explore Crinetics Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.21 B
Current Price
$40.25
52W High / Low
$57.99 / $25.83
Stock P/E
—
Book Value
$10.38
Dividend Yield
—
ROCE
-49.63%
ROE
-40.17%
Face Value
—
EPS
$-4.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
594
Beta
0.31
Debt / Equity
4.89
Current Ratio
12.32
Quick Ratio
12.3
Forward P/E
-9.67
Price / Sales
536.59
Enterprise Value
$3.15 B
EV / EBITDA
-6.14
EV / Revenue
409.33
Rating
Strong Buy
Target Price
$83.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Evaxion A/S | $4.49 | — | $37.11 M | — | -38.23% | -1% | $12.15 / $1.25 | $2.04 |
| 2. | Corbus Pharmaceuticals Holdings, Inc. | $10.62 | — | $188.36 M | — | -57.84% | -54.18% | $20.56 / $5.75 | $8.38 |
| 3. | Palatin Technologies, Inc. | $22.07 | — | $39.22 M | — | 478.76% | -3.79% | $31 / $2 | $6.53 |
| 4. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
| 5. | Virax Biolabs Group Limited | $0.14 | — | $1.05 M | — | -107.11% | -83.82% | $1.2 / $0.1 | $0.81 |
| 6. | Palisade Bio, Inc. | $2.5 | — | $414.71 M | — | -13.92% | -24.52% | $2.64 / $0.53 | $0.81 |
| 7. | Altimmune, Inc. | $3.56 | — | $463.05 M | — | -35.67% | -50.57% | $7.73 / $2.87 | $2.03 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 6.16 M | 0.14 M | 1.03 M | 0.36 M | 0 M |
| Operating Profit | -133.67 M | -142.59 M | -129.11 M | -111.41 M | -94.75 M |
| Net Profit | -122.81 M | -130.09 M | -115.64 M | -96.77 M | -80.59 M |
| EPS in Rs | -1.17 | -1.24 | -1.1 | -0.92 | -0.77 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 7.7 M | 1.04 M | 4.01 M | 4.74 M |
| Operating Profit | -516.77 M | -338.85 M | -222.61 M | -167.88 M |
| Net Profit | -465.32 M | -298.41 M | -214.53 M | -163.92 M |
| EPS in Rs | -4.44 | -2.85 | -2.05 | -1.57 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.13 B | 1.43 B | 635.35 M | 352.18 M |
| Total Liabilities | 134.17 M | 109.79 M | 96.25 M | 35.85 M |
| Equity | 992.08 M | 1.32 B | 539.11 M | 316.33 M |
| Current Assets | 1.05 B | 1.38 B | 574.15 M | 345.18 M |
| Current Liabilities | 85.07 M | 59.68 M | 43.94 M | 27.72 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -377.92 M | -230.19 M | -168.6 M | -115.2 M |
| Investing CF | 173.91 M | -574.82 M | -200.41 M | -173.98 M |
| Financing CF | 40.61 M | 1.01 B | 391.24 M | 121.96 M |
| Free CF | -383.68 M | -234.04 M | -173.29 M | -116.86 M |
| Capex | -5.76 M | -3.84 M | -4.69 M | -1.66 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -74.11% | -15.28% | — | — |
| Earnings Growth % | -39.1% | -30.88% | — | — |
| Profit Margin % | -28720.69% | -5345.85% | -3460.38% | — |
| Operating Margin % | -32613.47% | -5547.17% | -3544.06% | — |
| Gross Margin % | 100% | 100% | — | — |
| EBITDA Margin % | -32345.43% | -5519.81% | -3523.31% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.